MARKET NEWS

Daré Bioscience Announces Positive Topline Results From Phase 3 Trial
Kronos Bio Announces FDA Clearance of IND for Oral CDK9 Inhibitor
Ionis Announces Initiation of the Global Phase 3 BALANCE Study
Cerner & Elligo to Make Clinical Trials Accessible for Health Systems of All Sizes
Catalent to Invest $10 Million to Expand High Potency Containment Capabilities for Micronization
BioAge Raises $90 Million to Treat Aging & Age-Related Diseases

  FEATURED EDITORIAL

  COMPANY PROFILE

HCmed Innovations focuses on the development of drug-device combination products for inhalation therapy. It develops and manufactures portable vibrating mesh nebulizers that offer a mature customization platform, aiming to enhance drug delivery. This technology enables efficient and reliable nebulization of different types of medication, ranging from small molecule synthetics to large molecule biologics, as either solutions, suspensions or even difficult-to-deliver high viscosity drugs. Click here for more.

  EXCLUSIVE ONLINE CONTENT

New Clinical Trial Data Demonstrates BD Libertas Wearable Injector as a Drug Delivery System

New Clinical Trial Data Demonstrates BD Libertas Wearable Injector as a Drug Delivery System

BD (Becton, Dickinson and Company) recently announced publication of the results from a 52-subject human clinical trial with the BD Libertas Wearable Injector…..

Passage Bio Teams With Catalent to Start cGMP Manufacturing for Lead Gene Therapy Products

Passage Bio Teams With Catalent to Start cGMP Manufacturing for Lead Gene Therapy Products

Passage Bio, Inc. and Catalent recently announced that manufacturing operations have commenced to support adeno-associated virus (AAV) production for Passage Bio’s lead….

Syneos Health & ConcertAI Announce Strategic Collaboration to Accelerate the Use of Real World Evidence & AI to Advance Oncology Research

Syneos Health & ConcertAI Announce Strategic Collaboration to Accelerate the Use of Real World Evidence & AI to Advance Oncology Research

Syneos Health and ConcertAI recently announced a strategic collaboration to accelerate and streamline the implementation of novel oncology clinical trial research and study designs…..

Theratechnologies Announces New Findings for its Lead Investigational Compound for the Treatment of Several Additional Cancers

Theratechnologies Announces New Findings for its Lead Investigational Compound for the Treatment of Several Additional Cancers

Theratechnologies Inc. recently announced new preclinical in vivo findings regarding the efficacy and tolerability of its novel investigational proprietary peptide-drug conjugate (PDC), TH1902, for the….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

January 6 – Capsules
January 13 – Excipients